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ABSTRACT
TheUL111A gene of human cytomegalovirus encodes a viral homologue of the cellular immunomodulatory cytokine interleukin 10
(cIL-10), which, due to alternative splicing, results in expression of two isoforms designated LAcmvIL-10 (expressed during both lytic
and latent infection) and cmvIL-10 (identified only during lytic infection).Wehave analyzed the functions of LAcmvIL-10 during la-
tent infection of primarymyeloid progenitor cells and found that LAcmvIL-10 is responsible, at least in part, for the known increase in
secretion of cellular IL-10 andCCL8 in the secretomes of latently infected cells. This latency-associated increase inCCL8 expression
results froma concomitant LAcmvIL-10-mediated suppression of the expression of the cellularmicroRNA (miRNA) hsa-miR-92a,
which targets CCL8directly. Taking the data together, we show that the previously observed downregulation of hsa-miR-92a andup-
regulation ofCCL8duringHCMV latent infection ofmyeloid cells are intimately linked via the latency-associated expression of
LAcmvIL-10.
IMPORTANCE
HCMV latency causes significant morbidity andmortality in immunocompromised individuals, yet HCMV is carried silently
(latently) in 50 to 90% of the population. Understanding howHCMVmaintains infection for the lifetime of an infected individ-
ual is critical for the treatment of immunocompromised individuals suffering with disease as a result of HCMV. In this study, we
analyze one of the proteins that are expressed during the “latent” phase of HCMV, LAcmvIL-10, and find that the expression of
the gene modulates the microenvironment of the infected cell, leading to evasion of the immune system.
The species-specific human cytomegalovirus (HCMV) is wide-spread within the human population: estimates of seropreva-
lence vary between 50% and 90%, depending on socioeconomic
factors (1). In healthy individuals, a robust T cell response to pri-
mary infection is believed to ensure that clinical symptoms rarely
occur.However, like all herpesviruses,HCMVpersists for life, and
this is mediated, at least in part, by its ability to enter a latent life
cycle (2, 3).
In general, latent infection of otherwise healthy carriers is also
asymptomatic, as is the sporadic reactivation of the virus, which is
believed to occur routinely in latently infected individuals in vivo.
However, in immunocompromised individuals (including AIDS
patients and transplant recipients), primary infection, as well as
reactivation from latency, carries a risk of severe morbidity and
mortality (2, 3).
The differences between lytic and latent infection with HCMV
are striking. Lytic infection is initiated by the expression of virus-
encoded immediate-early (IE) genes; the subsequent expression
of viral early (often viral DNA replication-associated) and late
(often viral packaging-associated) genes is followed by the release
of infectious virions. A number of cell types support lytic infec-
tion, including fibroblasts and endothelial cells, and this occurs
over 48 to 72 h in vitro (4). Conversely, in certain cell types, such as
undifferentiated monocytes and their CD34 progenitors, latent
infection can be established. During latency, the lytic transcrip-
tion program is heavily suppressed. This results in a lack of pro-
duction of infectious virions, and viral gene expression is re-
stricted to a substantially reduced number of latency-associated
transcripts (2, 3, 5–11). However, these latently infected cells can
reactivate virus as a result of their differentiation into macro-
phages and dendritic cells (DCs) (2, 3).
Despite a profoundly limited viral transcription profile, a sub-
stantial number of changes in cellular gene expression are known
to occur during latent infection of myeloid cells with HCMV (12–
14), including changes to cellular microRNAs (miRNAs) (15), as
well as changes to the cellular secretome (16, 17). For example, in
latently infected CD34 cells, the upregulation of the cellular
chemokine CCL8 acts as a CD4 T cell chemoattractant, but con-
comitant increases in latency-associated secretion of other immu-
nomodulatory factors, such as transforming growth factor 
(TGF-) and cellular interleukin 10 (cIL-10), neutralizes the ef-
fector functions of these recruited T cells (16). Although latency-
associated regulation of the cellularmiRNAhsa-miR-92a has been
implicated in the control of cIL-10 expression during latency (15),
how latent infection modulates expression of, e.g., CCL8 is far
from clear.
Intriguingly, although latent HCMV infection robustly in-
duces expression of cIL-10, the virus also encodes IL-10 homo-
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logues. Two isoforms of virus-encoded IL-10 are generated by
alternative splicing from the viral UL111A gene. One of these is a
protein of 175 amino acids, termed cmvIL-10, which is expressed
during lytic infection and has the expression kinetics of a late gene
(18–20). The second isoform, predicted to consist of 139 amino
acids and termed LAcmvIL-10, has a C-terminal truncation and is
expressed during both lytic and latent infection (11, 21–23).
HCMV is not the only CMV that encodes a cellular IL-10 homo-
logue. An IL-10 homologue encoded by theUL111A open reading
frame (ORF) has also been identified in rhesus macaque CMV
(RhCMV). Although it has a slightly different gene structure than
cmvIL-10, like cmvIL-10, it shows low amino acid identity to host
cellular IL-10 (20).
Although the full-length cmvIL-10 gene has only 27% amino
acid identity to the human cIL-10 gene, cmvIL-10 has a number of
functions in common with cIL-10: it forms homodimers and
binds the cIL-10 receptor (24); it triggers STAT3 phosphorylation
and activation of the JAK/STAT signaling pathway (23, 25); it
signals via the phosphoinositide-3-kinase pathway, contributing
to cytokine suppression (26); and it shares the ability of cIL-10 to
prevent NF-B activity via inhibition of IKK (26).
In contrast, LAcmvIL-10 appears quite dissimilar to cIL-10 and
cmvIL-10. Although, like cIL-10 and cmvIL-10, it can downregu-
late major histocompatibility complex (MHC) class II in latently
infected granulocyte/macrophage progenitors (GMPs) (11, 22), it
either does not signal through the IL-10 receptor (IL-10R) or it
engages the receptor in a different way than cIL-10 and cmvIL-10
(23). Consequently, there is a dearth of knowledge regarding the
functions of LAcmvIL-10 during latency.
We now show that, during latent infection of myeloid cells,
LAcmvIL-10 mediates the known latency-associated increase in
secreted cellular CCL8 and that this is due to concomitant sup-
pression by LAcmvIL-10 of expression of the cellular miRNA hsa-
miR-92a, which in itself contributes to a number of effects during
latency (15), as well as targeting CCL8 directly.
MATERIALS AND METHODS
Cells and viruses. CD34 hematopoietic progenitor cells from the pe-
ripheral blood of granulocyte colony-stimulating factor (G-CSF)-mobi-
lized donors were resuscitated as described by the manufacturer (Lonza)
and maintained in X-vivo 15 (Lonza) in the absence of serum or growth
factors. Primary CD14 monocytes were isolated from venous blood, as
described previously (27). The purity of isolated monocytes was deter-
mined by flow cytometric detection of CD14 cells, resulting in mean
CD14 populations of 98.1%. TheMerlin bacterial artificial chromosome
(BAC) (28) was used to generate the UL111A deletion virus and the re-
vertant, as previously described (29).
Proteins. Recombinant LAcmvIL-10 and the control protein were
generated as described previously (22).
qPCR and RT-qPCR. For the quantification of hsa-miR-92a, the
Cell-CT reverse transcription-quantitative PCR (RT-qPCR) kit (Am-
bion)was usedwith specific primers andTaqMan probes to hsa-miR-206,
and hsa-miR-92a was analyzed relative to the housekeeping miRNA hsa-
miR-16 using standard parameters, as described previously (15).
For the quantification of IE transcript, RNA was isolated using the
miRNeasy minikit and amplified using the Quantitect virusROX virus
kit (Qiagen). The IE and UL138 (gene 138 of the unique long viral-ge-
nome region) transcripts were amplified alongside the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) housekeeping transcript using the
following primers and probes: IE, CAAGAACTCAGCCTTCCCTAAGAC
and TGAGGCAAGTTCTGCAATGC with the probe (FAM [6-carboxyfl
uorescein])CCAATGGCTGCAGTCAGGCCATG(TAMRA [6-carboxyte
tramethylrhodamine; Sigma]), and GAPDH, GGAAGCTTGTCATC
AATG and CCCCACTTGATTTTGGAG with the probe (JOE [Sigma])A
TCACCATCTTCCAGGAGCGAG(BHQ1 [black hole quencher 1]). The
viral transcript UL138 was detected with primers CGCTGTTTCTCTGG
TTAG and CAGACGATACCGTTTCTC with the probe (Cy5)CCGACG
ACGAAGACGATGAAC(BHQ2). Samples were analyzed and processed
with an ABI 7500 Fast Real Time machine using MicroAmp Fast Optical
96-well reaction plateswith the followingRTparameters: 50°C for 20min,
followed by heat inactivation at 95°C for 5min and then the PCR steps (50
cycles of 95°C for 15 s and 60°C for 45 s).
Virus genome quantification was carried out using a qPCR as de-
scribed previously (30), modified to remove the preamplification PCR
step.
The quantification of RT-qPCR products was performed either by the
calculation of CT values as described previously (15) or by a direct
determination of HCMV copy numbers from theWHOHCMV standard
control curve, as previously described (30).
Semiquantitative PCR. For the validation of latency, RNA was iso-
lated from CD34 cells using TRIzol (Invitrogen), and RT-PCRs were
performed for IE72 (IE), UL138, and GAPDH for 20 cycles of amplifica-
tion under previously published conditions (15, 21). Cellular IL-10 was
quantified using primers 5=-GCCTAACATGCTTCGAGATC and 5=-TG
ATGTCTGGGTCTTGGTTC after RNA was extracted using an Analytik
Jena RNA kit and first-strand cDNA amplified using an Agilent Affinity
Script qPCR cDNA synthesis kit, and a qPCR was run with 2 Brillina II
SYBR Green qPCRmaster mix (Agilent Technologies) at 95°C for 10 min
and then 40 cycles consisting of 95°C for 15 seconds and 60°C for 45 s.
Fluorescence-activated cell sorting (FACS).Monocytes were treated
with 50 ng/ml of recombinant LAcmvIL-10 or a control protein for 24 h.
The treated monocytes were harvested and then stained with HLA-DR
allophycocyanin (APC) antibody (BD Biosciences). Following fixation,
the samples were acquired on a FACSCalibur (BD Biosciences) and ana-
lyzed using Flowjo software (TreeStar Inc.).
Enzyme-linked immunosorbent assay (ELISA). For CCL8, superna-
tants were quantified using the RayBiotech kit. For IL-10, supernatants
were assayed using the Quantikine kit (R&D Systems).
Cell viability assay. Cells were stained with trypan blue, and the blue
cells were enumerated.
RESULTS
Validation of the UL111A deletionmutant virus during HCMV
latency in primary myeloid cells. It has previously been reported
that HCMV expresses two different isoforms of viral IL-10 (vIL-
10), resulting from differential splicing, which have been desig-
nated cmvIL-10 and LAcmvIL-10 (11, 19, 20). LAcmvIL-10 is
known to be expressed during both HCMV lytic and latent infec-
tion (11, 21). However, to date, expression of cmvIL-10 has been
described only during lytic infection.
In order to test the role of LAcmvIL-10 during latent infection,
we generated a recombinant virus in which the complete UL111A
open reading frame had been deleted. A UL111A deletion virus
has been previously characterized (31), but it was based on the
extensively passaged AD169 laboratory isolate of HCMV devoid
of the UL-b= region of the genome, which is known to carry a
number of viral genes important for immune evasion and latent
infection (8, 32–35). Consequently, we generated the equivalent
UL111A deletion in the clinical isolateMerlin and tested its ability
to undergo latent infection in primary myeloid cells. Figure 1A
shows that, after experimental latent infection of CD34 cells,
both wild-type (WT) virus and the UL111A deletionmutant virus
(deltaUL111A) expressed the latency-associated viral UL138 RNA
in the absence of viral IE transcription, consistent with latent in-
fection in these cells. LAcmvIL-10 was also detected in CD34
Poole et al.
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cells latently infected withWT or revertant virus but, as expected,
was not detected after latent infectionwith the deltaUL111A virus.
We also confirmed these observations in a second model of
HCMV latency. Figure 1B shows that CD14monocytes latently
infected with WT or revertant virus also expressed both UL138
and LAcmvIL-10, but no LAcmvIL-10 was detectable in these cells
latently infected with deltaUL111A virus.
deltaUL111A virus is less efficient at establishing latency in
CD34 myeloid progenitors and CD14 monocytes. Previous
studies, using an AD169 deltaUL111A virus, have shown little dif-
ference in the ability of this vIL-10 deletion mutant to undergo
latent infection in GMPs (36).
In contrast, using the Merlin clinical isolate, the lack of
UL111A did show a decrease in the establishment of latent infec-
tion of CD14 monocytes, as well as in latently infected CD34
cells. In these cells, the levels of latency-associated expression of
UL138 were qualitatively lower in both CD34 and CD14
monocytes when cells were latently infectedwith the deltaUL111A
virus thanwhen theywere infectedwith either theWTor revertant
(Fig. 1A and B), which was confirmed quantitatively by RT-qPCR
(Fig. 2A and B). These analyses suggest that the establishment of
latency with clinical isolates of HCMV is less efficient in the ab-
sence of LAcmvIL-10 in these myeloid cell types.
In order to determine why deltaUL111A virus appeared to
show a reduced efficiency of latent carriage, at least on the basis of
levels of latent expression ofUL138, we quantified the efficiency of
genome carriage in cells latently infected with wild-type or
deltaUL111A virus. Figure 2C (graphs a and b, respectively) show
that, although the number of input genomes used to infect CD34
and CD14 cells were equivalent for all virus isolates, the number
of deltaUL111A virus genomes carried by both cell types after 10
days of latency was clearly reduced compared to the wild-type or
revertant virus (Fig. 2C, graphs c and d). To determine whether
this was due to differential cell death, latently infected cells were
analyzed by trypan blue exclusion. Consistent with the decrease in
genome carriage, cells latently infected with deltaUL111A virus
showed increased levels of cell death compared to either wild-type
or revertant virus in both CD34 and CD14 progenitor cells
(graphs e and f, respectively). These data demonstrate that
LAcmvIL-10 is likely to play a role in enhancing cell survival, a
property it may share with cIL-10, which is known to increase
cell survival in myeloid progenitors generally and during
HCMV latency (15).
Recombinant LAcmvIL10 is functionally active.To assess the
potential role of LAcmvIL-10 in the maintenance of latent viral
genomes, a recombinant bacterially expressed LAcmvIL-10 pro-
tein was generated, as previously described (22). To confirm the
functionality of the proteins, we first analyzed their abilities to
downregulate MHC class II; both the LAcmvIL-10 and cmvIL-10
proteins have been shown to reduce MHC class II cell surface
expression on treated GMPs (22). Figure 3 shows that, as ex-
pected, treatment of CD14 monocytes with LAcmvIL-10 re-
sulted in decreased expression of MHC class II, confirming the
functionality of the purified recombinant LAcmvIL-10.
Recombinant LAcmvIL-10 upregulates cellular IL-10 via a
decrease in cellular hsa-miRNA-92a. Latent infection of CD34
progenitors with theMerlin isolate ofHCMV is known to result in
an increase in secreted cIL-10. This is an important survival factor
for primary myeloid progenitor cells, such as CD34 and CD14
cells (15, 37–39). Furthermore, since cIL-10 is known to autoregu-
late its own expression, we reasoned that at least one function of
latency-associated expression of viral IL-10 could be to help
modulate cIL-10 expression. Consequently, we tested whether
the LAcmvIL-10 protein had any effect on the expression of
cIL-10 in myeloid cells. Figure 4A shows that, as expected,
latent infection of CD14 cells results in increased secretion of
cellular IL-10, and interestingly, treatment of CD14 cells with
recombinant LAcmvIL-10 also led to time-dependent induc-
tion of cIL-10. These results were verified at the transcription
level, which again indicated concomitant increases in levels of
cIL-10 transcript upon LAcmvIL-10 treatment (Fig. 4B).
Our previous work has also shown that the latency-associated
increase in cellular IL-10 results, at least in part, from a latency-
associated decrease in the cellular miRNA hsa-miR-92a (15).
However, how latent infection affects this decrease in hsa-miR-
92a is unclear. As LAcmvIL-10 increased cIL-10 expression, we
reasoned that this effect might also be mediated through an effect
of LAcmvIL-10 onhsa-miR-92a. Consequently, we testedwhether
treatment of myeloid cells with the LAcmvIL-10 protein altered
expression of hsa-miR-92a. Figure 4C shows that LAcmvIL-10
FIG1 LAcmvIL-10 is transcribed during experimental latency in bothCD34 cells andCD14monocytes. CD34 (A) or CD14 (B) cells were latently infected
with HCMV for 9 days and then harvested for GAPDH, UL138, LAcmvIL-10, or IEmRNA as indicated and analyzed by RT-PCR in the presence () or absence
() of reverse transcriptase enzyme. Mock, mock infected; Rev, revertant.
HCMV Latency-Associated Viral IL-10 Function
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protein clearly reduced the levels of hsa-miR-92a RNA compared
to controls or the cIL-10 protein. Consistent with this, when la-
tencywas established inCD14 cells using the deltaUL111A virus,
the latency-associated decrease in hsa-miR-92a was abrogated
compared to revertant virus (Fig. 4D).
These data suggest, therefore, that LAcmvIL-10 may be a sig-
nificant contributing factor to the latency-associated decrease in
cellular hsa-miR-92a and the concomitant increase in expression
of cIL-10 that we have previously observed upon latent infection
of CD34 cells (15, 16).
The downregulation of hsa-miR-92a by LAcmvIL-10 also
causes CCL8 upregulation due to direct targeting of CCL8 by
hsa-miR-92a. We have previously shown that, in addition to the
upregulation of cIL-10 in the secretomes of latently infected cells,
there is also an increase in secretion of the cellular chemokine
CCL8 (16). Interestingly, CCL8 is a predicted target of hsa-miR-
92a using computer prediction algorithms (such as EBI [http:
//www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/v5/] and
Targetscan [http://www.targetscan.org]). To confirm that CCL8
mRNA is directly targeted by hsa-miR-92a, we carried out lu-
ciferase-based assays in which the predicted target of hsa-miR-92a
in the 3= untranslated region (UTR) of CCL8 was cloned into a
luciferase expression vector and assayed for levels of luciferase
expression after cotransfection with an hsa-miR-92a mimic. Fig-
ure 5A (right graph) shows that hsa-miR-92a was indeed able to
decrease luciferase expression, and conversely, an antagomir to
FIG 2 HCMV lacking UL111A has decreased capacity for establishing latency. (A and B) Primary CD14 or CD34monocytes were latently infected withWT,
revertant, or deltaUL111A HCMV for 10 days and analyzed for UL138 RNA levels by qRT-PCR. The graphs represent CT values from two experiments. (C)
(a to d) Alternatively, cells were lysed for DNA extraction after infection to assess genome input (a and b) or after the establishment of latency at 10 days (c and
d). (e and f) After 10 days, the cells were also stained with trypan blue to assess cell survival. The data represent two biological replicates of triplicate samples plus
standard deviations.
Poole et al.
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hsa-miR-92a led to an increase in levels of luciferase. In contrast,
hsa-miR-92a did not suppress luciferase expression from the pa-
rental luciferase vector (Fig. 5A, left graph).
We next tested whether LAcmvIL-10 was able to affect levels of
endogenous cellular CCL8 expression in myeloid primary cells.
Figure 5B shows that, as expected, latent infection of CD14
monocytes resulted in an increase in secreted CCL8, similar to our
previous observations in latently infectedCD34 cells (16). Treat-
ment of CD14 monocytes with recombinant LAcmvIL-10 also
resulted in a substantial induction of CCL8 expression (Fig. 5B).
The levels of CCL8 induced by LAcmvIL-10 were also much
higher than those in latently infected cells, suggesting, perhaps,
that much lower levels of LAcmvIL-10 are actually expressed by
latently infected cells.
Consistent with these observations, when latency was estab-
lished using the deltaUL111A virus, no such induction of CCL8
was observed (Fig. 5C). This argues that LAcmvIL-10 is the pri-
mary regulator of CCL8 induction during HCMV latency.
FIG 3 LAcmvIL-10 causes downregulation of MHC class II. CD14 mono-
cytes were incubated in the presence of recombinant LAcmvIL10 or control
protein at 50 ng/ml for 24 h before fixing and staining for HLA-DR and anal-
ysis by FACS.
FIG 4 Recombinant LAcmvIL-10 causes cIL-10 upregulation and hsa-miR-92a downregulation. CD14 cells were treated with the LAcmvIL-10 protein (A, B,
and C) or infected with HCMV deltaUL111a virus or the revertant (A and D), and then supernatants from cells treated with the indicated recombinant proteins
were assayed for levels of cellular IL-10 by ELISA (A) or harvested for cIL-10 RNA quantitation (B) or cells were harvested and assayed for levels of hsa-miR-92a
by RT-qPCR (C and D). The data represent two biological replicates of duplicate (A) or triplicate (B, C, and D) samples. The error bars indicate standard
deviations.
HCMV Latency-Associated Viral IL-10 Function
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DISCUSSION
Previous work has underscored the importance of the regulation
of the microenvironment around cells latently infected with
HCMV; it helps cell survival, as well as aiding immune evasion
(15–17). Although some of the mechanisms by which latent vi-
ruses mediate such changes are starting to be addressed (8, 15, 16,
40–43), a more detailed understanding of how latency-associated
changes impact the basic biological properties of the cell, to the
advantage of latent virus, and how they are mediated by latent
infection is crucial.
Although there are conflicting reports on the exact spectrumof
viral gene expression duringHCMV latency in themyeloid lineage
(2, 3, 5–11), it is clear that, in comparison to the lytic transcription
program, the latency-associated transcriptome is heavily sup-
pressed (2, 3, 44, 45). Expression of a number of viral genes has
been confirmed during natural latency, and latency-associated
functions for some of them (8, 40, 46), including LAcmvIL-10 (41,
43), have been posited.
Most reported functions of HCMV-encoded IL-10 have de-
scribed the effects of cmvIL-10. They include the inhibition of
secretion of proinflammatory cytokines by lipopolysaccharide
(LPS)-stimulated peripheral blood mononuclear cells (PBMCs),
monocytes, monocyte-derived DCs (MDDCs), and plasmacytoid
DCs (PDCs) (18, 21, 25, 41, 47); the stimulation of DCmigration
toward peripheral lymphnodes (18); and the stimulation of B cells
(23). Most pertinent to our study, cmvIL-10 can induce cIL-10
expression.
A number of studies have also directly compared the functions of
cmvIL-10 with those of LAcmvIL-10. Most have observed that cm-
vIL-10 shares more functions with cIL-10 than LAcmvIL-10 does.
For example, as observed for cIL-10, cmvIL-10, butnot LAcmvIL-10,
increases the expression of the fragment crystallizable IgG (FC) re-
ceptorsCD32 andCD64, aswell as FC receptor-mediated phagocy-
tosis (48). Similarly, like cIL-10, cmvIL-10 inhibits the expression of
proinflammatory cytokines in LPS-stimulated MDDCs, whereas
LAcmvIL-10 does not (21, 22).
One function common to cmvIL-10 and LAcmvIL-10 is the
ability of both recombinant proteins to downregulate MHC class
II in vitro (Fig. 3). However, there have been fewer studies analyz-
ing the effects of LAcmvIL-10 in the context of latent infection.
Previous studies suggested that LAcmvIL-10 decreases the differ-
entiation of CD34 progenitors into DCs (43), as when latency
was established with a virus lacking UL111A, the expression of
cytokines associated with DC formation was increased, and con-
sequently, the number of myeloid DCs in the population was also
increased (43).Our study now shows that LAcmvIL-10 plays a role
in regulating cellular miRNA expression and that this affects the
levels of specific secreted cellular proteins.
FIG 5 hsa-miR-92a targets CCL8, and LAcmvIL-10 causes CCL8 upregulation. (A) CD14 cells were transfected with an empty luciferase vector (left graph) or
with a luciferase vector containing the 3= UTR of CCL8 (3=CCL8) (right graph) in the presence or absence of hsa-miR-92a mimic (92a), as well as with an
hsa-miR-92a antagomir (Anti-92a), as indicated, and luciferase levels were plotted relative to untreated controls. (B and C) CD14 cells were also treated with
the indicated recombinant proteins and then assayed for levels of secreted CCL8 by ELISA (B), or CD14 cells were infected with either the viral IL-10 deletion
virus (deltaUL111A) or a revertant virus, and following the establishment of latency, the supernatants were assayed for levels of CCL8 by ELISA (C). The data
represent two biological replicates of triplicate (A and B) or duplicate (C and D) samples. The error bars indicate standard deviations.
Poole et al.
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HCMV is not the only herpesvirus to express a cIL-10
homologue. Virus-encoded homologues of cIL-10 are present
throughout the family Herpesviridae and emphasize the impor-
tance of the cytokine during virus infection (49). It is interesting
that the gammaherpesvirus Epstein-Barr virus (EBV) expresses a
homologue of cIL-10 (EBVIL-10) that has a much higher se-
quence homology to cIL-10 than HCMV-encoded IL-10 does.
Functionally, EBVIL-10mimicsmany of the immune-suppressive
properties of cIL-10 (50). Clearly, the expression of such an im-
mune-suppressive cytokine, whichwould impart clear advantages
for the virus, argues that there is a requirement for common func-
tions of this viral IL-10 during both virus life cycles. However, the
fact that HCMV also expresses an IL-10 isoform specific to latent
infection (LAcmvIL-10) suggests that certain additional functions
not common to cmvIL-10 are required specifically during latency.
As previously described for HCMV latency (15), EBV is also
known to alter the cellular miRNAome, and in particular the cel-
lular 17-92miRNA cluster, to affect the transcription of viral gene
products (51). However, the mechanism by which the cellular
17-92 miRNA cluster is regulated by latent EBV infection has not
been determined. Our observations now describe a novel role for
LAcmvIL-10 in the manipulation of cellular hsa-miR-92a, part of
the 17-92 miRNA cluster, during latent HCMV infection, which
in part explains the ability of HCMV to modulate the latency-
associated expression of two important secreted cellular proteins,
cIL-10 and CCL8 (16). The mechanism by which LAcmvIL-10
regulates hsa-miR-92a is not clear. Combinations of transcription
factors, such as p53, c-myc, DNMt1, DNMT3b, and REST, have
been shown to be important for the regulation of the transcription
of a number of cellular miRNAs (52, 53). However, we do know
that other members of the 17-92 miRNA cluster are not concom-
itantly downregulated during latent HCMV infection (15). Since
the whole cluster is likely to be regulated by the same promoter
(54), the mechanism by which LAcmvIL-10 specifically regulates
the levels of hsa-miR-92a are unclear. Similarly, whether LAcm-
vIL-10 also mediates any of the other latency-associated changes
in cellular miRNAs we have previously identified (15) is not
known but is under investigation.
It is becoming clear that, as well as targeting active lytic infec-
tion, targeting latent HCMV infection will be important to reduce
disease in a number of clinical settings (46). To date, all active
antiviral therapies for HCMV target lytic infection and so, by de-
sign, do not target latently infected cells. A proof of principle that
changes in latently infected cells could become targets for novel
antiviral therapies has recently been described (46), and it will
become increasingly important to expand such “latency-target-
ing” strategies.
Our view is that LAcmvIL-10, by enhancing cell survival,
impacts latent HCMV infection and carriage of latent genomes,
as reported here, as well as in a previously published report
suggesting that LAcmvIL-10 plays a role in myeloid differenti-
ation (43).
Our experiments do not distinguish between paracrine and
autocrine effects of LAcmv-IL-10. It is possible that prolife signals
resulting in enhancedmaintenance of the viral genome in latently
infected CD14 and CD34 cells result from the effects of se-
creted LAcmvIL-10 on bystander cells, which then impart a mi-
croenvironment conducive to latent carriage. Alternatively, se-
creted LAcmvIL-10 may act directly on the latently infected cell.
Regardless of the mechanism (paracrine, autocrine, or both), the
fact that cells latently infected with HCMV in the absence of LAc-
mvIL-10 are less able to maintain the latent genome argues for
biological relevance.
Consequently, LAcmvIL-10 could represent a viable therapeu-
tic target. In contrast to EBVIL-10, which has a high degree of
amino acid identity to cIL-10 (49), LAcmvIL-10 has much re-
duced homology. Consequently, it may lend itself more easily to
the generation of LAcmvIL-10-specific therapeutic antibodies
with little cross-reactivity with cIL-10 and thereby offer a poten-
tially simple strategy to target latently infected cells without off-
target effects on cIL-10.
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